CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Li Tzong Chen; Andrea Wang-Gillam; Yan Shen Shan; Teresa Macarulla; Jean Frédéric Blanc; Richard Hubner; Chang Fang Chiu; Gilberto Schwartsmann; Jens Siveke; Pipas J. Marc; Bruce Belanger; Floris de Jong; Khalid Mamlouk; Daniel Von Hoff

doi:10.1093/annonc/mdx263.016

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Li Tzong Chen, Andrea Wang-Gillam, Yan Shen Shan, Teresa Macarulla, Jean Frédéric Blanc, Richard Hubner, Chang Fang Chiu, Gilberto Schwartsmann, Jens Siveke, Pipas J. Marc, Bruce Belanger, Floris de Jong, Khalid Mamlouk, Daniel Von Hoff

臨床醫學研究所

研究成果: Article › 同行評審

原文	English
頁（從 - 到）	iii6-iii7
期刊	Annals of oncology : official journal of the European Society for Medical Oncology
卷	28
DOIs	https://doi.org/10.1093/annonc/mdx263.016
出版狀態	Published - 2017 6月 1

All Science Journal Classification (ASJC) codes

血液學
腫瘤科

存取文件

10.1093/annonc/mdx263.016

其它文件與鏈接

引用此

Chen, L. T., Wang-Gillam, A., Shan, Y. S., Macarulla, T., Blanc, J. F., Hubner, R., Chiu, C. F., Schwartsmann, G., Siveke, J., Marc, P. J., Belanger, B., de Jong, F., Mamlouk, K., & Von Hoff, D. (2017). CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii6-iii7. https://doi.org/10.1093/annonc/mdx263.016

Chen, Li Tzong ; Wang-Gillam, Andrea ; Shan, Yan Shen 等. / CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. 於: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; 卷 28. 頁 iii6-iii7.

@article{7da20c5775494036923601a01ed5f715,

title = "CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy",

author = "Chen, {Li Tzong} and Andrea Wang-Gillam and Shan, {Yan Shen} and Teresa Macarulla and Blanc, {Jean Fr{\'e}d{\'e}ric} and Richard Hubner and Chiu, {Chang Fang} and Gilberto Schwartsmann and Jens Siveke and Marc, {Pipas J.} and Bruce Belanger and {de Jong}, Floris and Khalid Mamlouk and {Von Hoff}, Daniel",

year = "2017",

month = jun,

day = "1",

doi = "10.1093/annonc/mdx263.016",

language = "English",

volume = "28",

pages = "iii6--iii7",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Chen, LT, Wang-Gillam, A, Shan, YS, Macarulla, T, Blanc, JF, Hubner, R, Chiu, CF, Schwartsmann, G, Siveke, J, Marc, PJ, Belanger, B, de Jong, F, Mamlouk, K & Von Hoff, D 2017, 'CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy', Annals of oncology : official journal of the European Society for Medical Oncology, 卷 28, 頁 iii6-iii7. https://doi.org/10.1093/annonc/mdx263.016

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. / Chen, Li Tzong; Wang-Gillam, Andrea; Shan, Yan Shen 等.
於: Annals of oncology : official journal of the European Society for Medical Oncology, 卷 28, 01.06.2017, p. iii6-iii7.

研究成果: Article › 同行評審

TY - JOUR

T1 - CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

AU - Chen, Li Tzong

AU - Wang-Gillam, Andrea

AU - Shan, Yan Shen

AU - Macarulla, Teresa

AU - Blanc, Jean Frédéric

AU - Hubner, Richard

AU - Chiu, Chang Fang

AU - Schwartsmann, Gilberto

AU - Siveke, Jens

AU - Marc, Pipas J.

AU - Belanger, Bruce

AU - de Jong, Floris

AU - Mamlouk, Khalid

AU - Von Hoff, Daniel

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85079680827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079680827&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx263.016

DO - 10.1093/annonc/mdx263.016

M3 - Article

C2 - 32135959

SN - 0923-7534

VL - 28

SP - iii6-iii7

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Chen LT, Wang-Gillam A, Shan YS, Macarulla T, Blanc JF, Hubner R 等. CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 6月 1;28:iii6-iii7. doi: 10.1093/annonc/mdx263.016